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Mutations in several mitochondrial DNA and nuclear genes involved in mitochondrial protein synthesis have recently been
reported in combined respiratory chain deficiency, indicating a generalized defect in mitochondrial translation. However, the
number of patients with pathogenic mutations is small, implying that nuclear defects of mitochondrial translation are either
underdiagnosed or intrauterine lethal. No comprehensive studies have been reported on large cohorts of patients with combined
respiratory chain deficiency addressing the role of nuclear genes affecting mitochondrial protein synthesis to date. We inves-
tigated a cohort of 52 patients with combined respiratory chain deficiency without causative mitochondrial DNA mutations,
rearrangements or depletion, to determine whether a defect in mitochondrial translation defines the pathomechanism of their
clinical disease. We followed a combined approach of sequencing known nuclear genes involved in mitochondrial protein
synthesis (EFG1, EFTu, EFTs, MRPS16, TRMU), as well as performing in vitro functional studies in 22 patient cell lines. The
majority of our patients were children (515 years), with an early onset of symptoms 51 year of age (65%). The most frequent
clinical presentation was mitochondrial encephalomyopathy (63%); however, a number of patients showed cardiomyopathy
(33%), isolated myopathy (15%) or hepatopathy (13%). Genomic sequencing revealed compound heterozygous mutations in
the mitochondrial transfer ribonucleic acid modifying factor (TRMU) in a single patient only, presenting with early onset,
reversible liver disease. No pathogenic mutation was detected in any of the remaining 51 patients in the other genes analysed.
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In vivo labelling of mitochondrial polypeptides in 22 patient cell lines showed overall (three patients) or selective (four patients)
defects of mitochondrial translation. Immunoblotting for mitochondrial proteins revealed decreased steady state levels of pro-
teins in some patients, but normal or increased levels in others, indicating a possible compensatory mechanism. In summary,
candidate gene sequencing in this group of patients has a very low detection rate (1/52), although in vivo labelling of mito-
chondrial translation in 22 patient cell lines indicate that a nuclear defect affecting mitochondrial protein synthesis is respon-
sible for about one-third of combined respiratory chain deficiencies (7/22). In the remaining patients, the impaired respiratory
chain activity is most likely the consequence of several different events downstream of mitochondrial translation. Clinical
classification of patients with biochemical analysis, genetic testing and, more importantly, in vivo labelling and
immunoblotting of mitochondrial proteins show incoherent results, but a systematic review of these data in more patients
may reveal underlying mechanisms, and facilitate the identification of novel factors involved in combined respiratory chain
deficiency.
Keywords: mitochondrial translation; combined respiratory chain deficiency; early-onset encephalomyopathy
Abbreviations: COX = cytochrome c oxidase; SDH = succinate dehydrogenase; TRMU = 5-methylaminomethyl-2-thiouridylate
methyltransferase
Introduction
Combined respiratory chain deficiency characterizes a subset of
mitochondrial diseases exhibiting decreased activities of multiple
complexes of the oxidative phosphorylation system, leading to
an impairment of ATP synthesis (DiMauro and Schon, 2003;
Smits et al., 2010a). Combined respiratory chain deficiency has
previously been associated with mitochondrial DNA rearrange-
ments (e.g. Kearns–Sayre syndrome) that affect mitochondrial
transfer RNA and/or ribosomal RNA genes (Tuppen et al., 2010)
leading to an overall decrease in respiratory complex function via
defective gene transcription and translation, or single mitochon-
drial transfer RNA point mutations resulting in dysfunctional trans-
lation of multiple mitochondrial respiratory complex subunit genes
(Hsieh et al., 2001; Karadimas et al., 2001).
Mitochondrial DNA depletion causes an overall reduction in
respiratory competency of the affected cell or tissue (Barthelemy
et al., 2001; Sarzi et al., 2007). Most patients with mitochondrial
DNA depletion carry autosomal recessive mutations in nuclear
genes participating in mitochondrial DNA replication, in the
balanced supply of deoxynucleotide triphosphates to mitochondria
or a component of the mitochondrial replisome (Spinazzola et al.,
2009). Mitochondrial DNA depletion is a frequent cause of severe
childhood (hepato)encephalomyopathies and is responsible for
50% of combined respiratory chain deficiencies in childhood
(Sarzi et al., 2007).
Nuclear DNA mutations can account for combined respiratory
chain deficiency by negatively affecting mitochondrial mainten-
ance, translation and/or transport. It has been hypothesized that
defective nuclear genes, which function in mitochondrial transla-
tion, are the primary cause of combined respiratory chain defi-
ciency in patients that present with neither mitochondrial DNA
mutations nor mitochondrial depletion (Jacobs and Turnbull,
2005; Smits et al., 2010b).
Miller et al. (2004) identified the first human disease related to
a nuclear-encoded impairment of mitochondrial protein synthesis
caused by a homozygous nonsense mutation in the ribosomal
protein gene MRPS16 (NG_008096.1; GI:193082974). Pathogenic
mutations of another mitoribosomal protein gene, MRPS22
(NG_012174.1; GI:237874203), have also been reported in severe
antenatal-onset infantile disease (Saada et al., 2007). The notion
that combined respiratory chain deficiency was correlated to a mu-
tation in a nuclear gene affecting mitochondrial translation prompted
further functional studies of mitochondrial translation in patients
with combined respiratory chain deficiency, which resulted in the
identification of mutations in mitochondrial translation elongation
factor genes EFG1 (GFM1; NG_008441.1; GI:197333723), EFTu
(TUFM; NG_008964.1 GI:212549715), EFTs (TSFM; NG_016971;
GI:62531056) and C12orf65 (NG_027517.1, GI: 304361771)
(Coenen et al., 2004; Antonicka et al., 2006, 2010; Smeitink
et al., 2006; Valente et al., 2007). Mutations in mitochondrial
transfer RNA modifying factors may also impair mitochondrial
translation, as in myopathy, lactic acidosis and sideroblastic anaemia
syndrome, a rare condition associated with mutations in the pseu-
douridylate synthase 1 gene (PUS1; NM_025215.5; GI:259155298;
Bykhovskaya et al., 2004; Fernandez-Vizzara et al., 2007). Very
recently, mutations were described in patients with myopathy,
lactic acidosis and sideroblastic anaemia syndrome in the mito-
chondrial tyrosyl transfer RNA synthetase gene (YARS2;
NC_000012.11; GI:224589803; Riley et al., 2010). Mutations in
nuclear genes encoding the mitochondrial aspartyl (DARS2;
NG_016138.1; GI:270289741) and arginyl (RARS2; NG_008601.1;
GI:201862389) transfer RNA synthetases were also described in very
characteristic neurological phenotypes, such as leucoencephalopa-
thy with brainstem and spinal cord involvement (Scheper et al.,
2007; Isohanni et al., 2010) and cerebellar and vermian hypoplasia
(Edvardson et al., 2007); however, not all these patients presented
with combined respiratory chain deficiency. Recently, autosomal
recessive mutations in the mitochondrial transfer RNA modifying
enzyme (TRMU; NG_012173.1; GI:237874202) were described in
infantile reversible hepatopathy (Zeharia et al., 2009) and were
also reported to modify the phenotype of the mitochondrial DNA
mutation m.1555A4G (Guan et al., 2006), opening up the possi-
bility that mitochondrial transfer RNA modifying factors may play
an important role in patients with combined respiratory chain
deficiency.
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To date, the number of patients identified as harbouring mutations
in nuclear genes affecting mitochondrial translation is very limited
(Table 1). To define whether combined respiratory chain deficiency is
attributed to nuclear defects in mitochondrial translation in patients,
we took two parallel approaches: (i) sequencing the genomic DNA
of known human candidate genes and (ii) in vivo metabolic
35S-methionine labelling of mitochondrial protein synthesis and
immunoblotting for two mitochondrial-encoded and one nuclear-
encoded proteins in human primary cells.
Materials and methods
Patients
We have investigated 52 patients with combined respiratory chain
deficiency, where mitochondrial DNA rearrangements, depletion and
point mutations were excluded as the underlying cause of the disease.
These patients were collected in two core mitochondrial diagnostic
centres (Newcastle and Munich) over 415 years. The clinical presen-
tation, histological and biochemical findings of the patients are sum-
marized in Table 2. DNA samples and primary cell cultures
(15 myoblast and 7 fibroblast cell lines, see Table 2) of these patients
were analysed in this study. Informed consent was obtained from
all participants in accordance with protocols approved by local
institutions.
Muscle histology and biochemistry
Muscle biopsies from all patients were investigated using standard
histological and histochemical assessments. Cryostat sections (10mm)
were stained for cytochrome c oxidase (COX), succinate dehydrogen-
ase (SDH) and sequential COX–SDH double histochemical staining to
identify COX-deficient fibres (Taylor et al., 2004). The activities of
respiratory chain complexes I–IV were determined and corrected for
citrate synthase activities in skeletal muscle and/or liver as described
earlier (Fischer et al., 1986; Tulinius et al., 1991; Kirby et al., 2007).
Fibroblast and myoblast tissue culture
Primary cell cultures from 22 of the 52 patients and also from four
controls were obtained from the Biobank of the Medical Research
Council Centre for Neuromuscular Diseases, Newcastle and the
Muscle Tissue Culture Collection, Munich (Table 2). Fibroblasts were
grown in minimal essential medium (Life Technologies, Paisley, UK),
supplemented with 10% foetal calf serum, 1% glutamine, 100 mg/ml
streptomycin, 100 U/ml benzylpenicillin, 110 mg/ml sodium pyruvate
and 50 mg/ml uridine. Muscle cells were grown in skeletal muscle
growth medium (PromoCell, Heidelberg, Germany), supplemented
with 4 mM L-glutamine and 10% foetal bovine serum and cultured
as recommended by the supplier.
DNA analysis
Genomic DNA was isolated from either primary cell lines or from
muscle biopsies, using the DNeasy Blood and Tissue kit (Qiagen,
Valencia, CA, USA). Genetic analysis for mitochondrial DNA
rearrangements and mitochondrial depletion was performed by stand-
ard methods (Murphy et al., 2008). Direct sequencing of the entire
mitochondrial genome was undertaken using muscle DNA as template,
employing 36 pairs of M13-tagged oligodeoxynucleotide primers as
described earlier (Taylor et al., 2003). Amplified polymerase chain
reaction products were sequenced using BigDye Terminator v3.1 che-
mistries (Applied Biosystems) and compared with the revised Cambridge
reference sequence (GenBank Accession number NC_012920) (Andrews
et al., 1999).
Cytogenetic analysis including comparative genomic hybridization
array was performed in patients with dysmorphological signs or con-
genital abnormalities. Whole genomic DNA was labelled, sephadex
G50 purified and hybridized together with human reference DNA
(400 ng each) on bacterial artificial chromosome arrays (CytoChip
V2.1, BlueGnome, Cambridge, UK) according to the manufacturer’s
protocol.
The entire coding region of the genes EFTs, EFG1 and EFTu was
sequenced by using M13-tailed intronic primers, as described earlier
(Valente et al., 2007). We designed primers for sequencing MRPS16
and TRMU (see online supplementary material). The analysis was per-
formed on an ABI 3130xl sequencer and the data analysed using
SeqScape program (Applied Biosystems). The impact of all identified
non-synonymous amino acid substitutions on protein function were
predicted using Sorting Intolerant From Tolerant software and by
Alamut (Interactive Biosoftware, Rouen, France). All synonymous
and intronic changes were analysed for the possibility of a splicing
defect by Alamut.
In vivo labelling and analysis of
mitochondrial protein synthesis
In vivo 35S-methionine labelling studies were performed as described
earlier (Chomyn et al., 1996) with the following modifications. Cells,
cultured to 60–70% confluency in T25cm2 flasks, were pretreated with
Dulbecco’s modified Eagle’s medium (Sigma, Poole, UK) containing
10% (v/v) foetal bovine serum, 50 mg/ml uridine and 50 mg/ml chlor-
amphenicol for 24 h at 37C/5% CO2. Cells were subsequently
washed with phosphate-buffered saline (Sigma, Poole, UK) and
incubated for 15 min at 37C/5% CO2 in methionine/cysteine and
foetal bovine serum-free Dulbecco’s modified Eagle’s medium, supple-
mented with 5% (v/v) dialyzed foetal bovine serum, 0.1 mg/ml
anisomycin (Sigma, Poole, UK). Following addition of 200 mCi/ml
35S-methionine/cysteine (35S EasyTag EXPRESS; Perkin Elmer,
Beaconsfield, UK), cells were incubated for 2 h at 37C/5% CO2,
then washed with phosphate-buffered saline and a cell pellet prepared.
Total protein yield was calculated by Bradford assay and equal
quantities of total protein (50 mg) were pretreated with 1U
Benzonase nuclease (Merck and Co., Inc, NJ, USA) for 1 h.
Pretreated samples were then separated by sodium dodecyl
sulphate–polyacrylamide gel electrophoresis. Radiolabelled proteins
were visualized by PhosphorImager/ImageQuant analysis (Amersham
Biosciences, Little Chalfont, UK). The identities of the mitochondrial-
encoded oxidative phosphorylation complex gene products were
identified in accordance with (Chomyn, 1996).
Immunoblotting
Immunoblotting was performed in six patient cell lines (Patients 9, 10,
12, 19, 32 and 36) and three controls. Aliquots of total protein
(5–20 mg) were loaded on 14% sodium dodecyl sulphate–polyacryl-
amide gels, transferred to polyvinylidene fluoride membranes and
subsequently probed with monoclonal antibodies recognizing porin
(Molecular Probes), mitochondrial COXI (Molecular Probes),
COXII (Mitosciences) or CI-20/complex I subunit CI-20/NDUFB8
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(Mitosciences) according to the recommendations of the suppliers.
Following incubation with horseradish peroxidase-conjugated
secondary antibodies (Dako, Denmark A/S) detected proteins were
visualized by ECL-plus (GE Healthcare). COXI and COXII are
mitochondrial-encoded proteins. The presence of NDUFB8 shows
good correlation with the correct assembly of mitochondrial-encoded
complex 1 subunits.
Results
Clinical presentation
The clinical presentation of the 52 patients with combined respira-
tory chain deficiency is summarized in Table 2. The vast majority
(50/52; 96%) of our patients were children (age of onset
515 years), most of them (34/52; 65%) had an early onset of symp-
toms within the first year of life; however, there were two adults
with onset at age 16 (Patient 38) and 27 (Patient 52) years. The
mean age of onset was 2.5 years. The most frequent clinical pres-
entation of children with combined respiratory chain deficiency––
similar to other early-onset mitochondrial conditions––was muscular
hypotonia and muscle weakness (50/52; 96%), accompanied by
encephalopathy (33/52; 63%), cardiomyopathy (17/52; 33%) and
hepatopathy (7/52; 13%). Some children showed very severe,
early-onset multisystem phenotypes, with symptoms already at
birth (13/52; 25%), in some infants accompanied by congenital
developmental anomalies (5/52; 9.5%) and rarely with dysmorpho-
logical signs. All patients except two showed muscular hypotonia and
weakness, but the involvement of other organs was more heteroge-
neous (encephalopathy, cardiomyopathy, hepatopathy). Two
patients (4%) did not show muscular hypotonia, but a predominant
liver dysfunction, either isolated (Patient 37) or in combination with
encephalopathy (Patient 39). Some rare additional symptoms were
also noted in a few cases such as agenesis of the corpus callosum
(n = 3) or other brain MRI abnormalities [white matter lesions
(n = 2), calcification of the nucleus caudatus (n = 1), basal ganglia
lesions (n = 1) and severe cortical atrophy (n = 1)]. Deafness was
reported in three patients. Cellular immunodeficiency, pancytopenia,
arthrogryposis, renal tubular acidosis, optic atrophy and intestinal
pseudo-obstruction were present in single patients only. Although
there were some clinical similarities defined in small number of
patients, such as patients with liver disease, cardiomyopathy or
agenesis of the corpus callosum, there was a substantial overlap,
making it difficult to form homogeneous phenotypic groups.
Patient 37 had a characteristic clinical presentation of reversible
isolated liver disease with no clinical involvement of skeletal muscle
or any other tissue.
Muscle histology and biochemistry
Muscle histochemistry showed COX-deficient and/or SDH hyper-
reactive fibres in 33 patients (63%). SDH hyper-reactive fibres,
suggesting mitochondrial proliferation, were noted in 14 patients
(27%), COX-deficient fibres were detected in 22 patients (42%),
and both SDH hyper-reactive and COX-deficient fibres were pre-
sent in two patients only. Muscle histochemistry was normal in
15 patients (29%) indicating that these findings are frequent, but
not necessarily present in all patients and normal mitochondrial
histochemistry does not exclude combined respiratory chain defi-
ciency. No correlation was found with the clinical phenotype. Lipid
accumulation was detected in six patients, implying a possible link
with lipid metabolism. Muscle histology and histochemistry data
were not available in four patients.
All patients showed significant reduction in activity levels in
more than one respiratory chain complex. Fifteen children (29%)
had a defect of all mitochondrial DNA-encoded enzymes (I, III,
IV), but with normal complex II activity clearly indicating a gen-
eralized problem of mitochondrial protein synthesis. Other patients
showed decreased activities of two or more complexes in different
combinations. The most frequent combination was I + IV defects,
detected in 31 children (60%). Decreased activities of I + III or
I + II/III––that may reflect a defect in coenzyme Q10 biosynthe-
sis––were observed in four patients (8%). A defect of II/III + IV
was found in two patients only. The biochemical defect was
very severe (510% residual activity of more than one respiratory
chain enzyme) in nine patients (17%), most of whom had a severe
early-onset multisystem phenotype; however, patients with a
milder biochemical defect do not necessarily present with a less
severe disease. In Patient 37, the respiratory chain deficiency was
expressed in both liver and muscle, the latter tissue not being
clinically affected, indicating that tissue-specific differences may
occur.
Genetic analysis
Mitochondrial DNA analysis was performed on all patient samples
to exclude mitochondrial DNA deletions/depletion or patho-
genic mutations. A homoplasmic COI mitochondrial DNA variant,
m.7444G4A, was detected in Patient 9, which is most likely not
pathological for the disease. However, no further possible disease
causing mitochondrial mutations were identified in the remaining
patients and no patients showed a significant reduction in mito-
chondrial copy number, thereby excluding mitochondrial DNA
depletion. No chromosomal abnormalities were detected in any
of the patients.
We detected two compound heterozygous TRMU mutations in
Patient 37 (Fig. 1). The heterozygous 1 base pair insertion
c.711_712insG causes a frameshift and premature stop after
252 amino acids (p.Gln238Ala fsX14), which is clearly pathogenic.
This mutation was heterozygous in the healthy mother. The second
mutation is a heterozygous nine base pairs in-frame insertion,
c.1081_1082insAGGCTGTGC, causing the insertion of three amino
acids in position p.361 (alanine, valine, arginine). This insertion
neighbours a highly conserved glutamine residue, which has been
shown to be involved in anticodon recognition, with mutation of this
residue resulting in an inactive enzyme (Numata et al., 2006).
Presumably altering the position of this critical residue due to an
insertion may inhibit the activity of TRMU. This variant was hetero-
zygous in the healthy father. Both mutations were absent in
100 normal chromosomes of the same ethnic origin (German and
British). In three additional patients (Patients 4, 27 and 49) we have
detected another missense variant in TRMU, c.28G4T, p.Ala10Ser
either in heterozygous (Patients 4, 27) or homozygous (Patient 49)
state, which has been reported earlier in healthy controls
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(National Centre for Biotechnology Information, rs11090865). None
of these patients had hepatopathy.
By sequencing the other nuclear genes that might affect mito-
chondrial protein synthesis, we identified a total of three single
heterozygous non-synonymous nucleotide changes in three differ-
ent genes (c.34T4C, p.Tyr12His in MRPS16; c.860T4A,
p.Leu287His in EFTs; c.1990G4A, p.Val664Ile in EFG1) in three
independent patients, but all three changes are listed in the
National Centre for Biotechnology Information database as single
nucleotide polymorphisms.
In vivo labelling and analysis of
mitochondrial translation products
Three of the 22 patients’ cells (Patients 1, 19 and 36) showed a
significant overall reduction in mitochondrial oxidative phosphor-
ylation complex subunit protein abundance, when compared with
the control samples (Fig. 2), whereas selective impairment was
found in four additional patients (Patients 12, 16, 32 and 34).
To exclude loading or pipetting problems, these results were con-
firmed with different loading concentrations by repeated analysis.
Although mitochondrial DNA copy number was within normal
range in these patients’ muscle DNA, we cannot completely
exclude the possibility that the in vivo labelling result in these
patients is related to a decreased amount of mitochondria.
Two cell lines showed an isolated decrease in the translation
of NADH dehydrogenase (ND) subunit 4 (Patients 16 and 32),
suggesting that either the translation of ND4 is more sensitive
on 35S-methionine labelling assay, or an isolated translation
deficiency of this subunit is present; however, the combined
respiratory chain defect in the patients’ muscle is supportive of
the first explanation. Another patient had reduced steady state
levels of ND1, ND4 and ND5 subunits with normal ND2 (Patient
12), which may reflect an isolated complex I related problem;
however, both complex I and IV were decreased on biochemical
measurement of respiratory chain enzymes in this patient’s skeletal
muscle (Table 2). Myoblasts of Patient 9, carrying the homoplas-
mic mitochondrial DNA variant m.7444G4A contained a smaller
COXI mitochondrial protein, which is presumably due to the
homoplasmic MTCOI mitochrondrial DNA variant and is
suggestive of the potential perturbation of the protein structure,
and not for defective translation.
The translation products of COXI and ND4 were decreased in
Patient 34, which may reflect the impairment in the protein syn-
thesis of both complexes I and IV. Interestingly, a relatively high
number of cell lines showed normal or even stronger than normal
labelling (Fig. 2). Unfortunately, we did not have cells from the
patient carrying TRMU mutations (Patient 37).
Immunoblotting
Immunoblotting with monoclonal antibodies against the
mitochondrial-encoded COX (COXI, COXII) and complex I sub-
units (nuclear-encoded NDUFB8, indicative for ND proteins) con-
firmed the overall decrease detected in translation assay in Patient
19 (Fig. 3; Table 3). The reduced bands for all three mitochondrial
proteins in Patient 12 suggest that the decreased translation prod-
ucts of ND1, ND4 and ND5 on pulse labelling may reflect a trans-
lation defect of not only complex I, but also COX-related proteins,
as was suggested by the combined respiratory chain defect in this
patient’s skeletal muscle (Table 2), However, in contrast with the
Figure 1 Sequence electropherograms of the compound heterozygous TRMU mutations in Patient 37 (top). Both wild type and mutant
sequences are detailed. Inserted bases are highlighted (boxes). Alignment of C-terminal sequence of human TRMU with its homologs
(bottom). Mutant sequence with the three amino acid insertion in blue and the highly conserved shifted glutamine residue in red are
shown.
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Figure 2 35S-methionine pulse labelling of myoblast (A and B) and fibroblast (C) cell lines. Patients (P) 1, 19 and 36 showed a significant
overall reduction in mitochondrial oxidative phosphorylation complex subunits. Patients 32 and 16 showed an isolated decrease in the
translation of ND4. Patient 12 had reduced steady-state levels of ND1, ND4 and ND5, with normal ND2, and COXI and ND4 were
decreased in Patient 34. Patient 9 contained a structurally altered, smaller COXI mitochondrial protein. Deficient bands and lanes are
marked with white arrows and stars.
Figure 3 Immunoblotting for mitochondrial proteins COXI, COXII, NDUFB8 (representing ND subunits) and porin as a control protein in
patients’ primary cell lines (P) compared with controls (C). Patients 12 and 19 showed an overall decrease of all three mitochondrial
respiratory chain proteins COXI, COXII and NDUFB8. In Patients 10, 32 and 36 we detected normal and even stronger than normal signals
for COXI, COXII and NDUFB8. In Patient 9, we could confirm the aberrant migration of COXI whilst the other mitochondrial-encoded
proteins were normal.
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overall repression of mitochondrial translation in Patient 36 and the
isolated decrease in translation of ND4 in Patient 32, we detected
normal and even stronger than normal signal on immunoblotting
with antibodies against COXI, COXII and NDUFB8 (Fig. 3; Table 3).
In Patient 9, carrying the mitochondrial DNA variant m.7444G4A,
consistent with the translation result, we confirmed the aberrant
migration of COXI whilst the other mitochondrial-encoded proteins
were normal (Fig. 3; Table 3). In Patient 10, both mitochondrial
translation and protein levels were higher than normal, indicating
a possible compensatory mechanism.
Discussion
Combined respiratory chain deficiency is relatively common in
mitochondrial encephalomyopathies and accounts for 30% of
all respiratory chain deficiencies (Smits et al., 2010a, b). Based
on our experience in mitochondrial diagnostics in both children
and adults, 40% of all combined respiratory chain deficiencies
can be explained by mitochondrial DNA deletions and point
mutations in mitochondrial transfer RNA genes, more frequently
affecting adult patients. However, single and multiple deletions do
not necessarily cause a biochemical respiratory chain deficiency.
Approximately 40% of combined respiratory chain deficiency
related to mitochondrial DNA depletion, affecting mostly young
children with variable clinical presentation, is caused by autosomal
recessive mutations in 9 nuclear genes (DGUOK, MPV17, POLG,
TYMP, TK2, SUCLA2, SUCLG1, RRM2B, PEO1) influencing mito-
chondrial DNA replication and maintenance (Spinazzola et al.,
2009). In the remaining 20% of combined respiratory chain
deficiencies, after excluding mitochondrial DNA deletions, deple-
tion and point mutations, no clear diagnostic pathway is currently
available to determine the cause of disease. The combinations
of enzyme deficiencies may indicate that certain pathways are
involved in the primary disease mechanism, although it is more
likely to reflect a defect of the overall mitochondrial protein syn-
thesis. In support of the second possibility, in patients with single
mitochondrial DNA rearrangements or mitochondrial transfer RNA
mutations, the respiratory chain deficiency may not affect all
enzymes with mitochondrial-encoded subunits (frequently isolated
complex I or I + IV defect, Tuppen et al., 2010).
We analysed 52 patients with combined respiratory chain defi-
ciency from two mitochondrial diagnostic centres. These individuals
underwent thorough mitochondrial investigations, but the underly-
ing cause was not identified. We focused our studies on investiga-
tions of mitochondrial translation, to define the frequency of a
defective protein synthesis in combined respiratory chain deficiency.
The clinical, histological and biochemical data of our patients
(Table 2) show similar clinical presentations (mitochondrial ence-
phalomyopathy, cardiomyopathy, isolated myopathy, hepatopathy
or multisystem disease) with the previously described patients
listed in Table 1. The vast majority of our patients were children
(age of onset 515 years) and most frequently had an early-onset
of symptoms 51 year of age (65%). Both in our collective and in
previously published reports a few children had a very severe,
early-onset multisystem disease accompanied by congenital devel-
opmental anomalies and/or dysmorphological signs, which are rare
presentations in other types of mitochondrial disease and may re-
flect a possible antenatal disease manifestation. It is also possible
that some nuclear defects of mitochondrial translation are intra-
uterine lethal.
We identified seven patients (15%) with an isolated muscle
involvement. The onset of symptoms was in most of these patients
at a very early age (first weeks or months of life) except for one child
who started to have muscle weakness at age 13 years. Because of the
similarities to a characteristic clinical syndrome, infantile reversible
COX deficiency myopathy, it is important to note that previous mito-
chondrial DNA sequencing excluded the m.14674T4C mutation in
all these patients as an underlying cause of the disease (Horvath
et al., 2009). In two adult patients, an isolated myopathy with a
probable muscle-specific defect of mitochondrial translation was
reported by Sasarman et al. (2002). However, the primary genetic
cause of the symptoms was not identified. Our patients with an
isolated myopathy and combined respiratory chain deficiency further
support the probability of a nuclear genetic factor controlling
mitochondrial translation only in skeletal muscle.
The candidate gene approach had a very low detection rate, the
primary causative mutations were detected in one patient only
(1/52, 2%). In Patient 37 with isolated, reversible hepatopathy, we
identified compound heterozygous mutations in the TRMU gene.
This child (Patient 37) has a very similar clinical presentation to the
previously published patients with TRMU mutations (Zeharia et al.,
2009), suggesting that TRMU mutations may lead to a clinically
recognizable liver-specific phenotype and should be screened in
all patients with early-onset hepatopathy. The possibility of a
Table 3 Correlation between 35S-methionine pulse labelling, immunoblotting and respiratory complex activities in
six patients
Patient 35S-methionine pulse labelling Immunoblotting Respiratory complex activity Muscle histochemistry
SDH+ COX–
P9 COXI faster migration COXI truncated band I + II/III + IV # – + + +
P10 Normal or overall" COXI, COXII, NDUFB8 " I + III + IV # + + + +
P12 ND1, ND4, ND5# COXI, COXII, NDUFB8 # I + IV # + –
P19 Overall# COXI, COXII, NDUFB8 # I + IV # + –
P32 Only ND4# COXI, COXII, NDUFB8 " I + II/III # – –
P36 Overall# COXI, COXII, NDUFB8 " I + IV # (liver) + –
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spontaneous recovery underlies the clinical importance in detecting
these patients in an early phase of disease. We have detected another
missense variant in TRMU, c.28G4T, p.Ala10Ser. This mutation
in homozygous form has been described to influence the pheno-
typic presentation of the mitochondrial m.1555A4G mutation
(Guan et al., 2006) and was detected compound heterozygous
with another pathogenic mutation in a child with reversible liver
disease (Zeharia et al., 2009). We have detected this variant more
frequently in the diagnostic work-up of patients without clinical
relevance and it is also present in controls (National Centre for
Biotechnology Information, rs11090865), therefore, we think that
this mutation, even if homozygous, is not sufficient to cause a
severe phenotype, as observed in our patients. None of the three
patients carrying the p.Ala10Ser mutation in either homozygous or
heterozygous form had liver problems.
The tissue-specific presentation of our patients indicate, as with
mitochondrial DNA depletion, that the phenotype may be repre-
sentative of the genetic defect; however, we cannot exclude that
mutations in several different genes may result in a similar pheno-
type. Complementation studies in patient cells would provide a
useful tool to further investigate these possibilities (Murano
et al., 1997; Sasarman et al., 2002).
We investigated the frequency of translational repression in
22 cell lines of patients with combined respiratory chain deficiency
by 35S-methionine pulse labelling. Pulse labelling studies detected
a defective mitochondrial translation in seven cell lines (32%),
thereby indicating that a nuclear defect of mitochondrial protein
synthesis may cause combined respiratory chain deficiency in
about one-third of patients, without mitochondrial DNA abnorm-
alities. However, the primary genetic cause was not detected by
candidate gene sequencing in any of the seven patients. Other
undefined molecular mechanisms are responsible for the combined
respiratory chain deficiency in about two-thirds of patients. Three
cell lines showed an overall decline in mitochondrial translation
(3/22, 13%), a selective defect of the translation of different
mitochondrial proteins was noted in four additional patients, indi-
cating that a defect of mitochondrial translation may not affect all
mitochondrial proteins. A selective defect of mitochondrial protein
synthesis of the COXI subunit was recently identified in patients
carrying pathogenic mutations in the TACO1 gene (Weraarpachai
et al., 2009), underlying the possibility that nuclear genes
may selectively affect the translation of different mitochondrial
proteins.
A relatively high number of cell lines showed normal or
enhanced pulse labelling, implying that either the combined re-
spiratory chain deficiency is tissue specific and not expressed in
cell culture, or related to factors downstream of protein synthesis.
We performed preliminary experiments to examine the oxidative
capacity of five cell lines that showed different patterns on
35S-methionine pulse labelling for mitochondrial translation
(Patients 9, 10, 12, 32, 36 and control cells). This detected
decreased levels of endogenous oxidative capacity in all cell
lines, indicating the presence of a respiratory chain deficiency. It
is important to note that recent reports have indicated normal or
relatively unaffected levels of de novo synthesis of mitochondrial
proteins, even after depletion of essential proteins involved in
mitochondrial translation, including the release and recycling
factors mitochondrial translational release factor 1 and mitochon-
drial ribosome recycling factor (Soleimanpour-Lichaei et al., 2007;
Rorbach et al., 2008). Thus, it should not be overlooked that cells
with severe respiratory defects may show apparently normal levels
of 35S methionine labelling. Other explanations may be that the
translated protein is unstable and triggers a compensatory increase
in transcription and translation. This data may also reflect that in
some patients, despite decreased translation, there is sufficient
protein for immunodetection, although it is possible that the
post-translational processing is altered. However, the respiratory
chain activities were decreased in muscle, possibly localizing the
defect downstream from mitochondrial translation (e.g. instability
of proteins or altered function).
In a large collective of patients with combined respiratory chain
deficiency we did not identify disease-causing mutations in EFG1,
EFTs, EFTu and MRPS16, highlighting the difficulty of genetic
diagnosis in these patients when using a candidate gene approach.
The only patient with identified pathogenic mutations had a char-
acteristic clinical presentation (reversible liver disease) that guided
the genetic analysis and led to the identification of mutations in
TRMU. In addition to TRMU mutations, deficiency of other
mitochondrial transfer RNA-modifying proteins (transfer RNA
pseudouridine synthase A, aspartyl-transfer RNA synthetase 2,
arginyl-transfer RNA synthetase 2) also show recognizable pheno-
types (Table 1). We suggest that a more thorough clinical char-
acterization of patients may provide diagnostic clues, which may
guide the otherwise inefficient candidate gene approach in com-
bined respiratory chain deficiency. It is highly likely that numerous
unknown disease genes are responsible for combined respiratory
chain deficiencies. Recently, a novel method that uses a combin-
ation of bioinformatics, phylogenetic studies and homozygosity
mapping (Pagliarini et al., 2008) was proven to identify novel
genes in complex 1 deficiency. This highly promising approach
may be used to dissect the complex molecular mechanisms
behind combined respiratory chain deficiencies.
In summary, thorough clinical characterization of patients with
combined respiratory chain deficiency may help to identify homo-
geneous patient groups, implicating a defect in single common
disease genes. This can be facilitated by linkage studies in large
consanguineous families or in groups of similarly affected small
families with similar clinical presentation. Functional cell culture
investigations directed at different levels of the regulation of mito-
chondrial function (transcription, translation, ribosome function,
protein stability, sub-complex formation) may provide a useful
complementary tool in selecting novel candidates in combined
respiratory chain deficiencies.
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